Appetite & Metabolic Control Program
A physician-guided weight management program using compounded semaglutide oral suspension for patients who may be clinically appropriate for GLP-1 treatment.
What's Included
- Licensed healthcare provider evaluation
- Prescription treatment when clinically appropriate
- Licensed pharmacy fulfillment when prescribed
- Ongoing clinical monitoring
- Private online care process
Appetite & Metabolic Control Program
Start the physician-guided process online. Your provider determines whether semaglutide treatment is appropriate and what treatment plan should be prescribed.
Enrollment or purchase does not guarantee that a prescription will be issued.
Your treatment continues through the clinical care process.
A medical intake questionnaire is required before a prescription is issued.
After consultation, you must be able to access and visualize your treatment plan.
Your patient-care experience must provide a way to contact your physician.
Addressing appetite at the hormonal level
Most weight management approaches focus primarily on behavior. Semaglutide works through GLP-1 receptor signaling, a pathway involved in the body's natural response to food and fullness.
GLP-1 signaling can help strengthen feelings of fullness, reduce appetite signaling and slow how quickly food leaves the stomach.
The goal is to support appetite regulation as part of a broader physician-guided weight management plan.
This is a compounded oral suspension.
This formulation is not the same as Ozempic, Wegovy or Rybelsus. Those are FDA-approved semaglutide products with different dosage forms and established product-specific evidence.
The compounded oral suspension may have different absorption characteristics. Results from FDA-approved semaglutide products should not automatically be assumed to apply to this formulation.
What GLP-1 signaling does in the body
Signals fullness
GLP-1 receptor activation supports stronger fullness signaling after eating.
Slows gastric emptying
Food may move through the stomach more slowly, extending the physical sensation of fullness after meals.
Reduces appetite signaling
Reduced baseline appetite may help decrease between-meal hunger and support lower caloric intake.
Supports glucose regulation
GLP-1 signaling also affects insulin and glucagon responses involved in blood sugar regulation.
Getting started is simple.
Your medical information is reviewed before any prescription treatment is issued.
Complete Your Medical Intake
Provide your health history, current medications, treatment goals and other relevant clinical information.
Licensed Provider Review
A licensed healthcare provider evaluates your information and determines whether treatment is clinically appropriate.
Prescription & Fulfillment
If approved, the prescription is sent to a licensed pharmacy for preparation and fulfillment.
Ongoing Monitoring
Your response, tolerance and treatment goals can be reviewed as your care continues.
Your treatment plan is based on your clinical profile.
Semaglutide treatment is not automatically appropriate for every patient. Your provider reviews relevant health information before deciding whether to prescribe treatment.
Medical history
Existing health conditions and relevant gastrointestinal history are considered during review.
Current medications
Your medication list is reviewed as part of determining treatment suitability.
Allergies & pregnancy status
Relevant allergies and pregnancy status are included in the clinical assessment.
Response & tolerance
Continued treatment decisions may be based on tolerance, response and individual clinical goals.
Treatment develops over time.
Response to GLP-1 treatment varies. Your provider may review tolerance, appetite response, side effects and weight-management goals as your treatment continues.
Adjustment & appetite changes
Gastrointestinal effects may be more noticeable during the adjustment period. Some patients begin noticing changes in appetite and fullness during early treatment.
Response is reviewed
Appetite effects and tolerance can become more established. Your provider determines whether continued treatment or changes to the treatment plan are clinically appropriate.
Maintenance is individualized
Longer-term care is guided by your individual response, treatment goals and the recommendations of your care team.
Clinical review comes first.
Semaglutide Oral Suspension is a compounded prescription medication. Compounded medications are not FDA-approved, and treatment is provided only when a licensed healthcare provider determines that it is clinically appropriate.
Before treatment
Your provider reviews your medical history, medications, allergies, pregnancy status, gastrointestinal history and other relevant factors.
Potential side effects
Potential side effects can include nausea, vomiting, constipation, diarrhea, abdominal discomfort, headache, fatigue, dizziness and reduced appetite.
Prescription required
Enrollment or purchase does not guarantee that a prescription will be issued. All treatment decisions are made independently by a licensed healthcare provider following clinical review.
What patients ask about Semaglutide Oral Suspension
Is this the same as Ozempic or Wegovy?
No. Ozempic and Wegovy are FDA-approved injectable semaglutide products. This program uses a compounded oral suspension, which is a different formulation and is not FDA-approved.
Is this the same as Rybelsus?
No. Rybelsus is an FDA-approved oral semaglutide tablet. This treatment uses a compounded oral suspension with a different formulation and preparation approach.
Will I experience nausea?
Nausea is a potential side effect of GLP-1 treatment. Gastrointestinal effects can be more noticeable during treatment adjustment and may improve as the body adapts. Contact your care team about persistent or concerning symptoms.
Does selecting this program mean I will receive Semaglutide?
No. Your provider determines the appropriate treatment based on your clinical profile. Another treatment approach may be recommended after medical review.
Do I still need to change my diet?
Yes. GLP-1 treatment can support appetite regulation, but it does not replace nutrition and lifestyle changes. Your treatment plan works alongside recommendations from your care team.
What happens if treatment is stopped?
Weight regain can occur after GLP-1 treatment is stopped, particularly when long-term dietary and lifestyle changes have not been established. Your provider can help plan ongoing weight-management care.
Semaglutide Oral Suspension is compounded and is not FDA-approved. The old treatment guidance identifies personal or family history of medullary thyroid carcinoma or MEN syndrome type 2 as contraindications and states that GLP-1 medications are contraindicated during pregnancy. Provider review is required.
Start the Appetite & Metabolic Control Program
Begin the private medical intake and let a licensed provider determine whether Semaglutide Oral Suspension is clinically appropriate for you.
Starting the process does not guarantee that a prescription will be issued.
Licensed provider evaluation Included in the care process
Prescription treatment When clinically appropriate
Licensed pharmacy fulfillment When prescribed
Ongoing clinical monitoring Individualized care
Semaglutide Oral Suspension is a compounded prescription medication. Compounded medications are not FDA-approved. Completing checkout or the medical intake does not guarantee that a prescription will be issued. Treatment is provided only when a licensed healthcare provider determines that it is clinically appropriate.
